Bayer (Cell Therapy Mfg)

Berkeley, CA
Find alternatives to Bayer (Cell Therapy Mfg) for Cell Therapy →
In-house manufacturer
126 confirmed programs · 51 sponsors · Last scored 2026-10-29
75.2
Signal Score
○ FDA Inspections ✓ Clinical Trials (126) ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: Bayer (Cell Therapy Mfg)

Signal Score
75.2/100 (as of 2026-10-29)
Quality Compliance
Assessment pending
Headquarters
Berkeley, CA
Modalities
Cell Therapy, Gene Editing
Active Programs
126 confirmed from ClinicalTrials.gov across 51 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Bayer (Cell Therapy Mfg)

CDMO.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations 94.6
126 active programs across 51 sponsors
Modalities: Gene Editing, Cell Therapy
83 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
126 active programs across 51 sponsors · Modalities: Gene Editing, Cell Therapy · 83 programs in advanced phases (Phase 2/3)
Programs 126
Sponsors51
ModalitiesCell Therapy, Gene Editing
126 active programs across 51 sponsors
Modalities: Gene Editing, Cell Therapy
83 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07566429 A Study of AB-1005 Gene Therapy in Japanese Adults With... PHASE2 Not Yet Recruiting
NCT07282847 A Study to Evaluate Safety, Tolerability, and Efficacy of... PHASE1/PHASE2 Recruiting
NCT06944522 A Study to Investigate the Efficacy and Safety of... PHASE3 Recruiting
NCT06914128 A Study of PRMT5 Inhibitor BAY 3713372 in Participants With... PHASE1/PHASE2 Recruiting
NCT06789445 A Study to Investigate the Safety of OpCT-001 in Adults Who... PHASE1/PHASE2 Recruiting
NCT06452277 A Study to Learn More About How Well Sevabertinib Works and... PHASE3 Recruiting
NCT06285643 A Study of AAV2-GDNF in Adults With Moderate Parkinson's... PHASE2 Recruiting
NCT04777851 Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage... PHASE3 Terminated
NCT05617885 Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer PHASE1 Completed
NCT05537740 A First-in-human Study to Learn How Safe the Study Drug... PHASE1 Active Not Recruiting
View all 126 programs →
Source: ClinicalTrials.gov · Retrieved Nov 22, 2026
Financial Stability 68.0
Parent company: Bayer AG
Financial assessment: 68.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: Bayer AG
Financial assessment: 68.0/100
Capacity 58.0
1 manufacturing site: Berkeley, CA
Modalities: Cell Therapy, Gene Editing
Capacity assessment: 58.0/100
Sites: Berkeley, CA
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
1 manufacturing site: Berkeley, CA
Modalities: Cell Therapy, Gene Editing
Capacity assessment: 58.0/100

Clinical Activity 126 studies

NCT07566429 A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's... PHASE2 Not Yet Recruiting NCT07282847 A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene... PHASE1/PHASE2 Recruiting NCT06944522 A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults... PHASE3 Recruiting NCT06914128 A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors PHASE1/PHASE2 Recruiting NCT06789445 A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary... PHASE1/PHASE2 Recruiting NCT06452277 A Study to Learn More About How Well Sevabertinib Works and How Safe it is... PHASE3 Recruiting NCT06285643 A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD) PHASE2 Recruiting NCT04777851 Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7 PHASE3 Terminated NCT05617885 Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer PHASE1 Completed NCT05537740 A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an... PHASE1 Active Not Recruiting NCT05236257 A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With... NA Completed NCT04572763 Copanlisib Plus Venetoclax in R/R DLBCL PHASE1/PHASE2 Active Not Recruiting NCT04999202 A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in... PHASE1 Terminated NCT04803123 Window Trial to Evaluate Molecular Response to PI3K Inhibition With... EARLY_PHASE1 Terminated NCT04895579 Lung Cancer With Copanlisib and Durvalumab PHASE1 Completed NCT04879368 RegoNivo vs Standard of Care Chemotherapy in AGOC PHASE3 Completed NCT04704154 A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can... PHASE2 Completed NCT04476329 Optimization for Regorafenib in HCC PHASE2 Terminated NCT04025372 INTREPId (INTermediate Risk Erection PreservatIon Trial) PHASE2 Active Not Recruiting NCT04156828 Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or... PHASE1 Terminated
+ 106 more studies
Source: ClinicalTrials.gov · Retrieved Nov 22, 2026

Hiring Activity Beta

From public job postings on the parent company's careers board, as of Nov 21, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No open roles were listed at this business's sites on Nov 21, 2026.
Coverage: read from the parent company's careers board and kept only postings at this business's sites (Berkeley, CA roles that name cell therapy in the title. Other Berkeley roles serve Bayer's own biologics and are left out, so this count may be low). Roles outside those sites are left out, and some of this unit's roles may be missed. Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source: jobs.bayer.com · Checked Nov 21, 2026 · Tracking since Oct 26, 2026

Frequently Asked Questions About Bayer (Cell Therapy Mfg)

How many clinical programs is Bayer (Cell Therapy Mfg) linked to?
Bayer (Cell Therapy Mfg) is associated with 126 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Bayer (Cell Therapy Mfg)'s CDMO Signal Score?
Bayer (Cell Therapy Mfg) has a Signal Score of 75/100, based on quality, operations, financial stability, and capacity data.
Evaluating Bayer (Cell Therapy Mfg) for a manufacturing program?
Use the free AI matchmaker to compare Bayer (Cell Therapy Mfg) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Cell Therapy CDMOs → Gene Editing CDMOs →

Similar CDMOs

Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
Green Phoenix Labs
San Diego, CA
Signal Score: 78.1
Cell Therapy, Gene Editing
Cedars-Sinai Biomanufacturing
Los Angeles, CA
Signal Score: 77.3
Cell Therapy, Gene Editing
Applied StemCell
Milpitas, CA
Signal Score: 59.0
Cell Therapy, Gene Editing
Poseida Therapeutics (CDMO)
San Diego, CA
Signal Score: 58.7
CAR-T, Cell Therapy, Gene Editing

Compare Bayer (Cell Therapy Mfg) with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Bayer (Cell Therapy Mfg)
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.